Dr. Jarjour is searching for novel methods to overcome resistance to immunotherapy. While immunotherapies have had a transformative impact for some patients suffering from specific cancers, some tumors are highly resistant to these treatments. These resistant tumors often lack the majority of immune cell types that could potentially attack the tumor. Dr. Jarjour is addressing this problem by developing antigen-independent methods to stimulate the innate proliferative capacity of tissue-resident CD8+ T cells, based on signaling molecules called cytokines. His generalizable approach could increase the efficacy of existing checkpoint blockade therapies on resistant tumors. His work has implications for many types of cancer, as well as vaccine development.
Damon Runyon Researchers
Meet Our ScientistsNicholas N. Jarjour, PhD
Project title: "Antigen-independent proliferation of tissue-resident memory T cells and therapeutic applications"
Institution: University of Minnesota
Award Program: Fellow
Sponsor(s) / Mentor(s): Stephen C. Jameson, PhD
Cancer Type: All Cancers
Research Area: Basic Immunology